Comparative Pharmacology
Head-to-head clinical analysis: ISOPAQUE 280 versus LIQUID E Z PAQUE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ISOPAQUE 280 versus LIQUID E Z PAQUE.
ISOPAQUE 280 vs LIQUID E-Z-PAQUE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Isopaque 280 (metrizoate) is an ionic, high-osmolar iodinated radiocontrast agent that attenuates X-rays by increasing the density of tissues where it distributes, thereby enhancing vascular and organ visualization during imaging.
Barium sulfate is a radiopaque agent that coats the mucosal surface of the gastrointestinal tract, attenuating X-rays and providing contrast on imaging studies.
Iohexol (ISOPAQUE 280) is administered intravenously, intra-arterially, or by other appropriate routes. Typical adult dose for CT imaging: 50–150 mL (concentration 280 mg I/mL) as a bolus or infusion. For angiography: 5–80 mL per injection, depending on procedure. Repeat doses may be given up to a total of 350 mL.
Oral: 25-50 mL (barium sulfate 60% w/v) as a single dose for upper GI series; for double-contrast studies, 100-200 mL (barium sulfate 250% w/v) as a single dose. Rectal: For barium enema, 200-300 mL of a 15-20% w/v suspension instilled via enema tube.
None Documented
None Documented
Terminal elimination half-life is 1.5–2 hours in patients with normal renal function; prolonged to >10 hours in severe renal impairment, requiring dose adjustment.
Not applicable (non-systemic agent); plasma half-life not clinically relevant.
Renal: approximately 95% of the dose is excreted unchanged in the urine within 24 hours via glomerular filtration. Fecal: <5%; biliary excretion is negligible.
Primarily fecal (oral route, unabsorbed); negligible renal excretion (<1% as intact drug).
Category C
Category C
Radiocontrast Agent
Radiocontrast Agent